FY2025 · ended Dec 31, 2025 · Revenue $67.67M, +16.9% YoY · Filed Feb 26, 2026
Intellia Therapeutics, Inc. (NTLA) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $67.7 million and a net loss of $412.7 million. Free cash flow was -$395.9 million. As of Sep 30, 2026 it held $614.8 million in cash and investments and $230.1 million in total debt.
Revenue (TTM)
$52.89M
-8.1% vs year-ago TTM
Net income (TTM)
$-426.14M
+4.4% vs year-ago TTM
Operating cash flow (TTM)
$-355.17M
+13.5% vs year-ago TTM
Free cash flow (TTM)
$-358.08M
+13.2% vs year-ago TTM
EPS (TTM)
$-3.35
+21.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
118.13M
+14.1% vs prior year
Net cash
$384.66M
as of Sep 30, 2026
Operating margin
-821.2%
FY 2026
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NTLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1652130
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M |
| Operating income | -$441.0M | -$534.3M | -$515.3M | -$458.2M | -$267.9M |
| Net income | -$412.7M | -$519.0M | -$481.2M | -$474.2M | -$267.9M |
| Diluted EPS | -$3.81 | -$5.25 | -$5.42 | -$6.16 | — |
| Operating cash flow | -$394.7M | -$348.9M | -$394.1M | -$333.3M | -$225.0M |
| Free cash flow | -$395.9M | -$354.7M | -$408.1M | -$346.8M | -$237.8M |
| Total assets | $842.1M | $1.2B | $1.3B | $1.5B | $1.3B |
| Total liabilities | $170.7M | $319.1M | $250.8M | — | — |
| Stockholders' equity | $671.4M | $872.0M | $1.1B | $1.2B | $1.0B |
| Cash and investments | $605.1M | $861.7M | $1.0B | $1.3B | $1.1B |
| Total debt | $93.3M | $210.2M | $115.3M | $130.7M | $74.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Sep 4, 2026 | Sep 4, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
All 721 Intellia Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.